UBE2Z

Across TCGA pan-cancer cohorts, UBE2Z mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated UBE2Z data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher UBE2Z mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated UBE2Z expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where UBE2Z mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.688	0.925	<.001	47	view →
CCRCC	DFS	Quartile	All	0.615	0.929	<.001	14	view →
LSCC	OS	Median	All	0.825	0.941	.019	4	view →
HNSC	DFS	Median	All	0.975	0.928	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

UBE2Z–PDAC (DFS)

Open the PDAC breakdown →